NYLIM
CSTL icon

New York Life Investment Management’s Castle Biosciences CSTL Stock Holding History

New York Life Investment Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,516
Closed -$366K – 979
2024
Q1 		$366K Buy
+16,516
New +$359K ﹤0.01% 1087

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

New York Life Investment Management's CSTL Position: Q2 2024 in Review

New York Life Investment Management sold out of Castle Biosciences (CSTL) in Q2 2024, closing a stake of 16,516 shares — an estimated $366K sold.

New York Life Investment Management first reported a position in CSTL in Q1 2024 and held it in 1 quarter. The position peaked at $366K in Q1 2024. 159 funds tracked by Wall St. Rank hold CSTL as of Q2 2024.

  • New York Life Investment Management reported no remaining Castle Biosciences position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 16,516 Castle Biosciences shares in Q2 2024, an estimated $366K.
  • New York Life Investment Management first reported a position in Castle Biosciences in Q1 2024 and held it in 1 quarter.
  • New York Life Investment Management's Castle Biosciences position peaked at $366K in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.